Evidence map›Paper›PMID 42180978›Full record

ArticleTranslational cancer research2026

Nomogram prediction for breast cancer-specific survival in patients with ER

Li You, Yiman Ge, Jiangyan Yong, Yuye Li, Lingling Zhang, Qiongying Hu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Li You *Department of Laboratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Yiman Ge *Department of Laboratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Jiangyan Yong *Department of Laboratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Yuye LiAcademic Affairs Office, Yunnan University of Chinese Medicine, Kunming, China.
Lingling ZhangDepartment of Laboratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Qiongying HuDepartment of Laboratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Estrogen receptor (ER) Methods: Data on patients with ER Results: The current study encompassed 1,525 patients with ER-/PR-/HER2+ BC. Utilizing univariable and multivariable analyses, four independent predictors of age, lung metastasis, tumor size, and stage were identified and utilized to create nomograms. The area under the curve (AUC) for nomogram prediction of cancer-specific survival (CSS) at 1, 2, and 3 years was 0.825, 0.794, and 0.781 in the training set, and 0.864, 0.793, and 0.772 in the validation set. The C-index was 0.780 (SE: 0.007) and 0.742 (SE: 0.015). Additionally, the calibration curve demonstrated good agreement between the nomogram's results and the observed results. Conclusions: This study established a prognostic nomogram with reliable accuracy for patients with ER

Indexed as

Breast cancer (BC)human epidermal growth factor receptor 2 (HER2)nomogramSurveillance, Epidemiology, and End Results (SEER)

Identifiers

PMID42180978
PMCPMC13190666

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.